Qingdao Baiyang Pharmaceutical Co., Ltd. is currently engaged in entrusted production and CDMO business of oral solid dosage form products for B-certificate holders.

The company strictly establishes a entrusted production quality management system in accordance with the system of drug marketing authorization holders, and has a research and development registration team for Sino US dual reporting products. Currently, multiple products have been successfully sold in the US market.

The company has the strength in drug research and development, including osmotic pump technology, delayed release technology, local action technology, membrane control technology, skeleton sustained release technology, and insoluble drug solubilization technology. It also has several production workshops that meet the regulatory requirements of the Chinese and American markets, such as tablets (ordinary tablets, controlled release tablets, sustained-release tablets, etc.), capsules, granules, and dry suspensions. Currently, multiple products have completed CDMO business product handover and are in commercial production.